地塞米松对中重度ARDS合并COVID-19患者无呼吸机天数的影响:CoDEX随机临床试验
这项在巴西41个ICU开展的多中心随机开放标签试验,纳入299例COVID-19合并中重度ARDS患者,比较静脉地塞米松联合标准治疗与单纯标准治疗。
要点
- 地塞米松可增加COVID-19合并中重度ARDS患者28天内无呼吸机天数。
- 地塞米松组第7天SOFA评分显著低于标准治疗组。
- 28天全因死亡率、ICU-free天数等次要结局无显著差异。
核心结论
- 在COVID-19合并中重度ARDS患者中,静脉地塞米松联合标准治疗较单纯标准治疗显著增加28天内无呼吸机天数。
研究设计与样本
- 多中心、随机、开放标签临床试验,在巴西41个ICU开展,2020年4月17日至6月23日入组。
- 纳入COVID-19合并中重度ARDS(柏林定义)患者299例,地塞米松组151例,标准治疗组148例。
- 地塞米松用法:静脉20 mg/天×5天,随后10 mg/天×5天或至ICU出院。
- 试验在达到计划样本量350例前因相关研究发表而提前停止。
主要发现
- 28天全因死亡率、28天内ICU-free天数、28天机械通气持续时间及第15天6点序贯量表评分均无显著差异。
临床怎么用
- 对于COVID-19合并中重度ARDS的ICU患者,可考虑使用静脉地塞米松以增加无呼吸机天数。
- 使用地塞米松时需监测继发感染和血糖,及时调整胰岛素治疗。
局限性
- 试验因相关研究发表而提前停止,未达到计划样本量350例。
- 为开放标签设计,未设盲。
- 仅纳入巴西41个ICU的患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. OBJECTIVE: To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil. Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020. Final follow-up was completed on July 21, 2020. The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients. INTERVENTIONS: Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, plus standard care (n =151) or standard care alone (n = 148). MAIN OUTCOMES AND MEASURES: The primary outcome was ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation. Secondary outcomes were all-cause mortality at 28 days, clinical status of patients at day 15 using a 6-point ordinal scale (ranging from 1, not hospitalized to 6, death), ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, and Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) at 48 hours, 72 hours, and 7 days. RESULTS: A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled and all completed follow-up. Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P = .04). At 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7) vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, -1.16; 95% CI, -1.94 to -0.38; P = .004). There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, or the 6-point ordinal scale at 15 days. Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events. CONCLUSIONS AND RELEVANCE: Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04327401.
引用
- Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020. PMID: 32876695. doi:10.1001/jama.2020.17021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。